1. Home
  2. NTIC vs CRDF Comparison

NTIC vs CRDF Comparison

Compare NTIC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Technologies International Corporation

NTIC

Northern Technologies International Corporation

N/A

Current Price

$8.46

Market Cap

83.1M

Sector

Industrials

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.83

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTIC
CRDF
Founded
1970
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.1M
130.7M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
NTIC
CRDF
Price
$8.46
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
3.9K
686.2K
Earning Date
04-24-2026
01-01-0001
Dividend Yield
0.48%
N/A
EPS Growth
N/A
27.37
EPS
0.03
N/A
Revenue
$84,234,474.00
$365,993.00
Revenue This Year
$11.40
N/A
Revenue Next Year
$8.70
N/A
P/E Ratio
$280.00
N/A
Revenue Growth
N/A
49.61
52 Week Low
$6.77
$1.48
52 Week High
$11.48
$4.56

Technical Indicators

Market Signals
Indicator
NTIC
CRDF
Relative Strength Index (RSI) 42.16 45.54
Support Level $7.32 $1.51
Resistance Level $8.58 $2.41
Average True Range (ATR) 0.25 0.14
MACD -0.06 0.03
Stochastic Oscillator 10.90 55.00

Price Performance

Historical Comparison
NTIC
CRDF

About NTIC Northern Technologies International Corporation

Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: